198 related articles for article (PubMed ID: 12518184)
21. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
22. [Combination therapy in the therapeutic strategy of arterial hypertension].
Chamontin B; Amar J
J Hum Hypertens; 1995 Aug; 9 Suppl 4():S35-9. PubMed ID: 7674272
[TBL] [Abstract][Full Text] [Related]
23. Telmisartan/hydrochlorothiazide: a new fixed dose combination.
Maillard M; Burnier M
Expert Rev Cardiovasc Ther; 2005 May; 3(3):375-86. PubMed ID: 15889965
[TBL] [Abstract][Full Text] [Related]
24. Rationale for the use of very-low-dose combinations as first-line treatment of hypertension.
Waeber B; Brunner HR
J Hypertens Suppl; 2001 Nov; 19(4):S3-8. PubMed ID: 11848261
[TBL] [Abstract][Full Text] [Related]
25. [Antihypertensive first-line and add-on treatment with a fixed controlled release combination of metoprololsuccinate/hydrochlorothiazide. Prospective doctor's office observational study in 14,964 patients].
Hildemann SK; Fischer HM; Pittrow D; Bohlscheid V
Fortschr Med Orig; 2003; 121(1):27-32. PubMed ID: 15117066
[TBL] [Abstract][Full Text] [Related]
26. [The rationale for drug combinations in the therapy of arterial hypertension].
Salvetti A; Virdis A; Di Venanzio L
Ann Ital Med Int; 1993 Oct; 8 Suppl():107S-110S. PubMed ID: 8117517
[TBL] [Abstract][Full Text] [Related]
27. Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection.
Gosse P
Expert Rev Cardiovasc Ther; 2006 May; 4(3):319-33. PubMed ID: 16716093
[TBL] [Abstract][Full Text] [Related]
28. [The long-term monotherapy with preparations from the 4 basic groups of antihypertensive agents of patients with mild and moderate arterial hypertension. The Multicenter Captopril and the Quality of Life Study. The working group of the Multicenter Captopril and the Quality of Life Study].
Metelitsa VI; Ostrovskaia TP; Duda SG; Filatova NP; Vygodin VA
Ter Arkh; 1995; 67(6):15-20. PubMed ID: 7667771
[TBL] [Abstract][Full Text] [Related]
29. The future of antihypertensive treatment.
Israili ZH; Hernández-Hernández R; Valasco M
Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
[TBL] [Abstract][Full Text] [Related]
30. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients.
Neutel JM
Curr Med Res Opin; 2008 Aug; 24(8):2389-401. PubMed ID: 18616863
[TBL] [Abstract][Full Text] [Related]
31. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
[TBL] [Abstract][Full Text] [Related]
32. Factorial antihypertensive study of an extended-release metoprolol and hydrochlorothiazide combination.
Papademetriou V; Hainer JW; Sugg J; Munzer D;
Am J Hypertens; 2006 Dec; 19(12):1217-25. PubMed ID: 17161766
[TBL] [Abstract][Full Text] [Related]
33. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
Jamerson KA; Nwose O; Jean-Louis L; Schofield L; Purkayastha D; Baron M
Am J Hypertens; 2004 Jun; 17(6):495-501. PubMed ID: 15177521
[TBL] [Abstract][Full Text] [Related]
34. A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertension.
Gleim GW; Rubino J; Zhang H; Shahinfar S; Soffer BA; Lyle PA; Littlejohn TW; Feig PU
Clin Ther; 2006 Oct; 28(10):1639-48. PubMed ID: 17157119
[TBL] [Abstract][Full Text] [Related]
35. Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials.
Waeber B
J Hypertens Suppl; 2006 May; 24(3):S19-27. PubMed ID: 16723862
[TBL] [Abstract][Full Text] [Related]
36. Low-dose combinations versus monotherapies in the treatment of hypertension.
Waeber B; Brunner HR
J Hypertens Suppl; 1997 Mar; 15(2):S17-20. PubMed ID: 9218193
[TBL] [Abstract][Full Text] [Related]
37. Update of diuretics in the treatment of hypertension.
Padilla MC; Armas-Hernández MJ; Hernández RH; Israili ZH; Valasco M
Am J Ther; 2007; 14(2):154-60. PubMed ID: 17414583
[TBL] [Abstract][Full Text] [Related]
38. Optimizing management of hypertension with combination therapy: considerations for the nurse practitioner.
Roberts ME; Epstein BJ
J Cardiovasc Nurs; 2009; 24(5):380-9. PubMed ID: 19707098
[TBL] [Abstract][Full Text] [Related]
39. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy.
Weir MR; Levy D; Crikelair N; Rocha R; Meng X; Glazer R
Am J Hypertens; 2007 Jul; 20(7):807-15. PubMed ID: 17586417
[TBL] [Abstract][Full Text] [Related]
40. A randomized, comparative study evaluating the efficacy and tolerability of losartan-low dose chlorthalidone (6.25 mg) combination with losartan-hydrochlorothiazide (12.5 mg) combination in Indian patients with mild-to-moderate essential hypertension.
Pareek A; Basavanagowdappa H; Zawar S; Kumar A; Chandurkar N
Expert Opin Pharmacother; 2009 Jul; 10(10):1529-36. PubMed ID: 19514864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
